|Articles|February 1, 2012

ACT December 2011 BPA Statement

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

ByAndy Studna, Senior Editor

July 20th 2026

Applying Systems Thinking to the Future of Clinical R&D

ByKelsey Jakee

July 17th 2026

© Gophotograph - © Gophotograph - stock.adobe.com

Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose

ByAndy Studna, Senior Editor

July 17th 2026

ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor

ByAndy Studna, Senior Editor

July 17th 2026

© Murrstock - © Murrstock - stock.adobe.com

Study Quantifies Financial Return of Risk-Based Quality Management in Oncology Trials

ByAndy Studna, Senior Editor

July 16th 2026

ACT December 2011 BPA Statement

Related Content

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

Applying Systems Thinking to the Future of Clinical R&D

Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose

ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor

Study Quantifies Financial Return of Risk-Based Quality Management in Oncology Trials

Trending on Applied Clinical Trials Online

Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose

FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development

ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor

Applying Systems Thinking to the Future of Clinical R&D

ACT Brief: CRO Partnership in Program Recruitment, Psychedelic Trial Design Guidance, and Breast Cancer Pathway Inhibitor